Skip to content

Alpha Tau Medical

US · DRTS #3046 by market cap Listed 1970
11.76 +0.45 +3.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 28.05 Expensive vs history 97th percentile
5-year average 3.93 · #490 of 513 in Biotechnology
P/E ratio -12.87 Cheap vs history 32nd percentile
5-year average -11.98
P/S ratio --
5-year average 0.00 · forward 569.32

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Alpha Tau Medical (DRTS) 1.09B -11.30 24.64 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value12.65 Economic moatNone UncertaintyVery High

Trading 7.6% below Morningstar's fair value estimate.

Fair value

Alpha Tau Medical Ltd earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $12.65 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's unfavorable dividend structure decreases our fair value estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% sits in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -4.0%, for example, falls in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

Alpha Tau Medical discussion 0 comments

Add a comment